Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by Impax Asset Management Group plc

Impax Asset Management Group plc grew its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 470,603 shares of the company's stock after purchasing an additional 210,576 shares during the quarter. Impax Asset Management Group plc owned approximately 1.01% of Pacira BioSciences worth $7,083,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of PCRX. Vanguard Group Inc. raised its stake in Pacira BioSciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock worth $149,413,000 after acquiring an additional 14,960 shares in the last quarter. Pacer Advisors Inc. raised its stake in Pacira BioSciences by 37.5% during the 2nd quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company's stock worth $61,877,000 after acquiring an additional 590,082 shares in the last quarter. Renaissance Technologies LLC raised its stake in Pacira BioSciences by 9.8% during the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company's stock worth $59,114,000 after acquiring an additional 184,000 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Pacira BioSciences by 12.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company's stock worth $52,300,000 after acquiring an additional 198,936 shares in the last quarter. Finally, Clearbridge Investments LLC grew its position in Pacira BioSciences by 2.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock worth $34,250,000 after purchasing an additional 26,463 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Truist Financial downgraded shares of Pacira BioSciences from a "buy" rating to a "sell" rating and lowered their price objective for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. StockNews.com downgraded shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Needham & Company LLC lowered their target price on shares of Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, August 12th. HC Wainwright lowered their target price on shares of Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Finally, Jefferies Financial Group lifted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $24.20.

Insider Activity

In related news, CEO Frank D. Lee purchased 8,264 shares of the business's stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the acquisition, the chief executive officer now directly owns 107,784 shares of the company's stock, valued at approximately $1,304,186.40. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders bought 11,176 shares of company stock worth $136,240. 6.40% of the stock is currently owned by company insiders.

Pacira BioSciences Trading Up 2.3 %

PCRX traded up $0.39 during trading on Wednesday, hitting $17.67. 726,515 shares of the company's stock were exchanged, compared to its average volume of 864,101. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.95. The stock has a 50 day moving average price of $15.48 and a 200 day moving average price of $21.11. The firm has a market cap of $815.12 million, a P/E ratio of 13.18 and a beta of 0.82.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.